KB-1083

BMS986340-hIgG1

12101

Home » BMS986340-hIgG1

Background of BMS986340-hIgG1

BMS-986340, a novel anti-CCR8 NF monoclonal antibody in development, led to measurable CCR8+ Treg depletion in human tumor explants. CCR8+ Treg depletion led to robust antitumor activity alone and in combination with anti-PD-1 in mouse tumor models. These results support further clinical evaluation of CCR8 depletion in combination with immune checkpoint blockade as a novel immunotherapy for cancer.

Specifications

Catalog Number	KB-1083
Antibody Name	BMS986340-hIgG1
Isotype	Human IgG1,kappa
FC Muations	Wild Type
Target	CCR8
Species Reactivity	Human
Host Cell Line	EXPI CHO
Purification Method	Affinity purified
Concentration	>2 mg/mL
Formulation	50 mM sodium citrate,150mM NaCl,pH5.5
Purity	>95% by SDS-PAGE and SEC-HPLC
Validation	FACS
Endotoxin Level	<0.2 EU/mg as determined by the LAL method
Sterility	0.2μm filtered
Storage	It is recommended that the protein should be aliquoted for optimal storage. Avoid repeated freeze-thaw cycles.
Stability	Stable for twelve months from date of receipt when stored at -20°C to -80°C; Stored at 2-8°C for one month without detectable loss of activity.

Characterization

Application

References

PB Silver, et al., Retina-specific T regulatory cells bring about resolution and maintain remission of autoimmune uveitis. J Immunol 194, 3011–3019 (2015).
J van Loosdregt, et al., Stabilization of the transcription factor Foxp3 by the deubiquitinase USP7 increases Treg-cell-suppressive capacity. Immunity 39, 259–271 (2013).